HIV 1 News and Research

RSS

Antibodies produced by newly developed mRNA vaccines are transferred from pregnant rabbits to offspring

Newly developed mRNA vaccines against Zika virus and HIV-1 produced strong antibody responses that transferred from pregnant rabbits to their offspring, researchers report March 24th in the journal Molecular Therapy.

24 Mar 2023

An automated bioinformatics pipeline to monitor HIV data in real-time

Researchers discuss an automated bioinformatics pipeline to prospectively and routinely analyze HIV-1 sequence data

15 Mar 2023

Self-directed autoantibodies against certain chemokines may protect against long-COVID

A recent study published in the journal Nature Immunology discovered autoantibodies against chemokines following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

8 Mar 2023

First-in-woman study of a non-hormonal vaginal film showed safety, potential contraceptive efficacy, and supports future development

Researchers developed a novel contraceptive 'ZB-06' a vaginal film containing a human contraceptive antibody called HC4-N that agglutinates sperm.

7 Mar 2023

Research details how the circadian and circannual cycles influence humans at the molecular level

The daily rotation of Earth and its yearly voyage around the Sun marks the natural rhythm of life on the planet.

13 Feb 2023

Analysis of rebound virus suggests two separate reservoirs of latent HIV in patients

When people living with HIV take antiviral therapy (ART), their viral loads are driven so low that a standard blood test cannot detect the virus.

1 Feb 2023

The impact of common viral infections on blood-brain barrier function and insulin sensitivity

A new study discusses the impact of several human viruses on blood-brain barrier function and insulin sensitivity.

31 Jan 2023

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute's HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.

19 Jan 2023

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers performed an epidemic dynamic analysis to assess the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)’s sub-VOC XBB.1.5 characteristics.

19 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

Researchers discover the Nrf3-mediated mechanism of melanogenesis

The skin is presumably the largest and one of the most versatile body organs. By providing a physical barrier, it protects our body from environmental assaults.

11 Jan 2023

Scientists explore synthesis of griffithsin in cell-free systems

A new study described the cell-free manufacturing of griffithsin (GRFT), a broad-spectrum antiviral protein.

28 Dec 2022

Miracles Start in the Lab: the quest to find a vaccine to cure AIDS

To commemorate World AIDS Day, News Medical spoke to Dr. Larry Corey, an internationally renowned expert in virology, immunology, and vaccine development, and the former president and director of Fred Hutch, about his work within the field of HIV/AIDS research and vaccine development.

30 Nov 2022

Study shows how HIV protein permanently alters immune cells

Though antiretroviral therapy has made HIV a manageable disease, people living with HIV often suffer from chronic inflammation.

22 Nov 2022

The biological properties of the SARS-CoV-2 E protein in the context of HIV-1

Researchers assessed the effectiveness of SARS-CoV and SARS-CoV-2 envelope proteins against HIV-1.

22 Nov 2022

β-cyclodextrin family found to be promising and cost-effective antiviral agents against SARS-CoV-2

Researchers identified β-cyclodextrins (β-CDs) as a safe and cost-effective drug against SARS-CoV-2 with a broad spectrum of activity.

18 Nov 2022

Researchers provide new insights into the vexing process that makes HIV stealthy

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.

14 Nov 2022

Researchers take a cue from viruses to make glioblastoma more vulnerable to treatment

In the tough war against glioblastoma, scientists are taking a cue from viruses on how to make the aggressive cancer more vulnerable to treatment.

1 Nov 2022

What is the impact of SARS-CoV-2 on HIV-1 infectivity?

In a new study, researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV envelope (E) proteins on human immunodeficiency virus type 1 (HIV-1) infectivity.

31 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022